Almanza-Aguiler E, Brunius C, et al, 2018

29877711

Impact in plasma metabolome as effect of lifestyle intervention for weight-loss reveals metabolic benefits in metabolically healthy obese women.

Almanza-Aguilera E, Brunius C, Bernal-Lopez M, Garcia-Aloy M, Madrid-Gambin F, Tinahones F, Gómez-Huelgas R, Landberg R, Andres-Lacueva C

Journal of Proteome Research

2018

17

8

2600-2610

Randomized Controlled Trial

High risk

Women aged 35-55; BMI >/r= 30 kg/m2; >o/= 1 of the following cardiovascular risk factors: elevated fasting glucose levels (plasma glucose >/=100 mg/dL), elevated blood pressure (systolic >/=135 or diastolic >/=85 mmHg or use of antihypertensive drugs), elevated triglycerides (>/=150 mg/dL or treatment with lipid-lowering medication), or decreased high-density-lipoprotein cholesterol (HDL) (<50 mg/dL).

Previous diagnosis of diabetes; pregnancy or planning to become pregnant during the study; cardiovascular disease; presence of any severe chronic illness; alcohol or drug abuse; undertaking a weight loss program that included physical activity or diet in the past three months.

(i) To determine the impact of an intensive lifestyle treatment for weight loss on the plasma metabolome, measured by untargeted 1H NMR metabolomics, in women defined as metabolically healthy obese (MHO) and (ii) to investigate the associations of weight loss and changes in other cardiometabolic risk markers with changes in metabolome after following the intervention.

See ROB 2.0

Spain

Government

Instituto de Salud Carlos III Fondo Europeo de Desarrollo Regional-FEDER Spanish Ministry of the Economy and Competitiveness (MINECO) Joint Programming Initiative “A Healthy Diet for a Healthy Life” CIBERFES (cofunded by the FEDER Program from the EU Generalitat de Catalunya’s Agency AGAUR